Literature DB >> 10586221

Rituximab for the treatment of type II mixed cryoglobulinemia.

F Zaja, D Russo, G Fuga, F Patriarca, A Ermacora, M Baccarani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10586221

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

2.  An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon.

Authors:  Endri Mauro; Mariangela Pedata; Anna Ermacora; Cesare Mazzaro
Journal:  Blood Transfus       Date:  2011-07-18       Impact factor: 3.443

Review 3.  Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC).

Authors:  Luca Quartuccio; Alessandra Bortoluzzi; Carlo Alberto Scirè; Antonio Marangoni; Giulia Del Frate; Elena Treppo; Laura Castelnovo; Francesco Saccardo; Roberta Zani; Marco Candela; Paolo Fraticelli; Cesare Mazzaro; Piero Renoldi; Patrizia Scaini; Davide Antonio Filippini; Marcella Visentini; Salvatore Scarpato; Dilia Giuggioli; Maria Teresa Mascia; Marco Sebastiani; Anna Linda Zignego; Gianfranco Lauletta; Massimo Fiorilli; Milvia Casato; Clodoveo Ferri; Maurizio Pietrogrande; Pietro Enrico Pioltelli; Salvatore De Vita; Giuseppe Monti; Massimo Galli
Journal:  Clin Rheumatol       Date:  2022-09-28       Impact factor: 3.650

Review 4.  Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.

Authors:  Dario Roccatello; Simone Baldovino; Daniela Rossi; Osvaldo Giachino; Morteza Mansouri; Carla Naretto; Debora Di Simone; Simona Francica; Roberto Cavallo; Mirella Alpa; Franca Napoli; Luigi M Sena
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 5.  Hepatitis C virus-related lymphoproliferative disorders: an overview.

Authors:  Anna-Linda Zignego; Carlo Giannini; Clodoveo Ferri
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 6.  Infectious etiology of vasculitis: diagnosis and management.

Authors:  Niveditha Mohan; Gail Kerr
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

Review 7.  Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.

Authors:  Freke Wink; Pieternella M Houtman; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 3.650

8.  Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.

Authors:  Teresa Urraro; Laura Gragnani; Alessia Piluso; Alessio Fabbrizzi; Monica Monti; Elisa Fognani; Barbara Boldrini; Jessica Ranieri; Anna Linda Zignego
Journal:  Case Reports Immunol       Date:  2015-03-01

9.  Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.

Authors:  Emily Comstock; Cheol-Woo Kim; Alison Murphy; Benjamin Emmanuel; Xi Zhang; Michael Sneller; Bhawna Poonia; Shyamasundaran Kottilil
Journal:  PLoS One       Date:  2017-12-11       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.